Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Exclusion Criteria

• •Use of routine prophylaxis of VWF-containing concentrates defined as at least 1 VWF-containing concentrate infusion to prevent or reduce bleeding per week during the previous 6 months prior to screening
• •Planning to initiate routine prophylaxis with VWF-containing concentrates or any other hemostatic treatment during the study
• •Patients with pro-thrombotic disorders or abnormal findings on laboratory thrombophilia evaluation performed at screening or previously documented
• •History of arterial or venous thrombosis, including superficial thrombophlebitis, or embolism
• •Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, or metabolic dysfunction
• •Baseline FVIII activity \> lower limit of normal (LLN)